Squamous cell carcinoma (SCC) of the head presents a significant challenge in achieving complete surgical excision while preserving function and aesthetics. Neoadjuvant intralesional methotrexate (MTX) has emerged as a potential strategy to reduce tumour burden preoperatively, facilitating more conservative surgical excisions. The results demonstrated significant lesion shrinkage, with a mean tumour size reduction of 68%, enabling less invasive surgical interventions.
Neoadjuvant Intralesional Methotrexate for Infiltrating Squamous Cell Carcinoma of the Head: A Case Series of 19 Patients
Briatico G.;Moscarella E.;Scharf C.;Nicoletti M. M.;Argenziano G.;Brancaccio G.
2025
Abstract
Squamous cell carcinoma (SCC) of the head presents a significant challenge in achieving complete surgical excision while preserving function and aesthetics. Neoadjuvant intralesional methotrexate (MTX) has emerged as a potential strategy to reduce tumour burden preoperatively, facilitating more conservative surgical excisions. The results demonstrated significant lesion shrinkage, with a mean tumour size reduction of 68%, enabling less invasive surgical interventions.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
